Leerink analyst Puneet Souda downgraded NeoGenomics (NEO) to Market Perform from Outperform with a price target of $9, down from $25. After a revenue miss, the FY25 guidance for 13%-15% growth “appears overly optimistic,” the analyst tells investors. Despite NeoGenomics being “the one-stop-shop in oncology diagnostics with a leading position in heme testing,” the firm sees a number of challenges emerging for the company, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics: Strategic Adjustments and Operational Efficiency Justify Buy Rating Despite Revenue Slowdown
- NeoGenomics: Strategic Positioning and Growth Potential Justify Buy Rating Despite Mixed Q1 Results
- NeoGenomics raises FY25 revenue view to $747M-$759M from $735M-$745M
- NeoGenomics reports Q1 EPS 0c, consensus (1c)
- NEO Upcoming Earnings Report: What to Expect?